CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Wang, Weiming ^a   Ye, Chaobaihui ^a   Liu, Jingjing ^a   Zhang, Di ^b   Kimata, Jason T ^c   Zhou, Paul ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; ENDONUCLEASE; LENTIVIRUS VECTOR; PROTEIN CAS9; RNA; SINGLE GUIDED RNA; UNCLASSIFIED DRUG; CRISPR ASSOCIATED PROTEIN; GUIDE RNA;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; GENE DISRUPTION; GENE MUTATION; GENE SILENCING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; CELL LINE; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRINAE; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; THERAPEUTIC USE; VIRUS ENTRY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

BASE SEQUENCE; CELL LINE; CRISPR-ASSOCIATED PROTEINS; GENETIC ENGINEERING; GENETIC THERAPY; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; LENTIVIRUS; RECEPTORS, CCR5; RNA, GUIDE; TRANSDUCTION, GENETIC; VIRUS INTERNALIZATION;

EID: 84919904581     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115987     Document Type: Article

References (56)

1. Ray N, Doms RW (2006) HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol 303: 97-120.
2. Shaw GM, Hunter E (2012) HIV transmission. Cold Spring Harb Perspect Med 2.
3. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, et al. (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273: 1856-1862.
4. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, et al. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367-377.
5. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, et al. (1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382: 722-725.
6. Nazari R, Joshi S (2008) CCR5 as target for HIV-1 gene therapy. Curr Gene Ther 8: 264-272.
7. Swan CH, Buhler B, Steinberger P, Tschan MP, Barbas CF, 3rd, et al. (2006) T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther 13: 1480-1492.
8. Chelli M, Alizon M (2001) Determinants of the trans-dominant negative effect of truncated forms of the CCR5 chemokine receptor. J Biol Chem 276: 46975-46982.
9. Akkina R, Banerjea A, Bai J, Anderson J, Li MJ, et al. (2003) siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. Anticancer Res 23: 1997-2005.
10. DiGiusto DL, Krishnan A, Li L, Li H, Li S, et al. (2010) RNA-Based Gene Therapy for HIV with Lentiviral Vector-Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma. Science Translational Medicine 2: 36ra43.
11. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, et al. (2008) Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26: 808-816.
12. Li L, Krymskaya L, Wang J, Henley J, Rao A, et al. (2013) Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther 21: 1259-1269.
13. Holt N, Wang J, Kim K, Friedman G, Wang X, et al. (2010) Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28: 839-847.
14. Maier DA, Brennan AL, Jiang S, Binder-Scholl GK, Lee G, et al. (2013) Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. Hum Gene Ther 24: 245-258.
15. Mussolino C, Morbitzer R, Lutge F, Dannemann N, Lahaye T, et al. (2011) A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res 39: 9283-9293.
16. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, et al. (2014) Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370: 901-910.
17. Makarova KS, Haft DH, Barrangou R, Brouns SJ, Charpentier E, et al. (2011) Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 9: 467-477.
18. Sampson TR, Saroj SD, Llewellyn AC, Tzeng YL, Weiss DS (2013) A CRISPR/Cas system mediates bacterial innate immune evasion and virulence. Nature 497: 254-257.
19. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, et al. (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337: 816-821.
20. Cong L, Ran FA, Cox D, Lin S, Barretto R, et al. (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823.
21. Mali P, Yang L, Esvelt KM, Aach J, Guell M, et al. (2013) RNA-guided human genome engineering via Cas9. Science 339: 823-826.
22. Jinek M, East A, Cheng A, Lin S, Ma E, et al. (2013) RNA-programmed genome editing in human cells. eLife Sciences 2.
23. Maggio I, Holkers M, Liu J, Janssen JM, Chen X, et al. (2014) Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells. Sci Rep 4: 5105.
24. Chang N, Sun C, Gao L, Zhu D, Xu X, et al. (2013) Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos. Cell Res 23: 465-472.
25. Dickinson DJ, Ward JD, Reiner DJ, Goldstein B (2013) Engineering the Caenorhabditis elegans genome using Cas9-triggered homologous recombination. Nat Methods 10: 1028-1034.
26. Friedland AE, Tzur YB, Esvelt KM, Colaiacovo MP, Church GM, et al. (2013) Heritable genome editing in C. elegans via a CRISPR-Cas9 system. Nat Methods 10: 741-743.
27. Jao LE, Wente SR, Chen W (2013) Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system. Proc Natl Acad Sci U S A 110: 13904-13909.
28. Shen B, Zhang J, Wu H, Wang J, Ma K, et al. (2013) Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res 23: 720-723.
29. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, et al. (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153: 910-918.
30. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, et al. (2013) One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154: 1370-1379.
31. Yu Z, Ren M, Wang Z, Zhang B, Rong YS, et al. (2013) Highly efficient genome modifications mediated by CRISPR/Cas9 in Drosophila. Genetics 195: 289-291.
32. Cho SW, Kim S, Kim JM, Kim JS (2013) Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31: 230-232.
33. Cho SW, Kim S, Kim Y, Kweon J, Kim HS, et al. (2013) Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res.
34. Cradick TJ, Fine EJ, Antico CJ, Bao G (2013) CRISPR/Cas9 systems targeting beta-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res 41: 9584-9592.
35. Ye L, Wang J, Beyer AI, Teque F, Cradick TJ, et al. (2014) Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc Natl Acad Sci U S A 111: 9591-9596.
36. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, et al. (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74: 8358-8367.
37. Wen M, Arora R, Wang H, Liu L, Kimata JT, et al. (2010) GPI-anchored single chain Fv - an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike. Retrovirology 7: 79.
38. Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, et al. (2012) Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol 86: 2715-2728.
39. Liu L, Wang W, Yang L, Ren H, Kimata JT, et al. (2013) Trimeric Glycosylphosphatidylinositol-Anchored HCDR3 of Broadly Neutralizing Antibody PG16 Is a Potent HIV-1 Entry Inhibitor. Journal of Virology 87: 1899-1905.
40. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L (2000) Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25: 217-222.
41. Tsai C, Caillet C, Hu H, Zhou F, Ding H, et al. (2009) Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine 27: 6777-6790.
42. He J, Choe S, Walker R, Di Marzio P, Morgan DO, et al. (1995) Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69: 6705-6711.
43. Liu L, Wen M, Wang W, Wang S, Yang L, et al. (2011) Potent and Broad Anti-HIV-1 Activity Exhibited by a Glycosyl-Phosphatidylinositol-Anchored Peptide Derived from the CDR H3 of Broadly Neutralizing Antibody PG16. Journal of Virology 85: 8467-8476.
44. Koyanagi Y, Miles S, Mitsuyasu R, Merrill J, Vinters H, et al. (1987) Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236: 819-822.
45. Freed EO, Myers DJ, Risser R (1989) Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. Journal of Virology 63: 4670-4675.
46. Shang H, Han X, Shi X, Zuo T, Goldin M, et al. (2011) Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China. J Biol Chem 286: 14531-14541.
47. Landry JJ, Pyl PT, Rausch T, Zichner T, Tekkedil MM, et al. (2013) The genomic and transcriptomic landscape of a HeLa cell line. G3 (Bethesda) 3: 1213-1224.
48. Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, et al. (2007) Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 360: 218-234.
49. Overbaugh J, Anderson RJ, Ndinya-Achola JO, Kreiss JK (1996) Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood. AIDS Res Hum Retroviruses 12: 107-115.
50. Theodore TS, Englund G, Buckler-White A, Buckler CE, Martin MA, et al. (1996) Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. AIDS Res Hum Retroviruses 12: 191-194.
51. Miller AD, Chen F (1996) Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry. J Virol 70: 5564-5571.
52. Hütter G, Nowak D, Mossner M, Ganepola S, Müßig A, et al. (2009) Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation. New England Journal of Medicine 360: 692-698.
53. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, et al. (2011) Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 117: 2791-2799.
54. Kim HJ, Lee HJ, Kim H, Cho SW, Kim JS (2009) Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. Genome Research 19: 1279-1288.
55. Zhou Y, Zhu S, Cai C, Yuan P, Li C, et al. (2014) High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509: 487-491.
56. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, et al. (2006) Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 103: 17372-17377.